Oncologix Tech (OTCMKTS:OCLG) vs. SurModics (OTCMKTS:SRDX) Head to Head Contrast

SurModics (NASDAQ:SRDX) and Oncologix Tech (OTCMKTS:OCLG) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.


This table compares SurModics and Oncologix Tech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SurModics 6.40% 7.47% 5.82%
Oncologix Tech N/A N/A N/A

Analyst Ratings

This is a summary of current ratings and target prices for SurModics and Oncologix Tech, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SurModics 0 1 2 0 2.67
Oncologix Tech 0 0 0 0 N/A

SurModics presently has a consensus price target of $58.00, indicating a potential upside of 69.64%. Given SurModics’ higher probable upside, equities analysts plainly believe SurModics is more favorable than Oncologix Tech.

Risk & Volatility

SurModics has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Oncologix Tech has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500.

Institutional and Insider Ownership

89.1% of SurModics shares are held by institutional investors. 7.7% of SurModics shares are held by company insiders. Comparatively, 39.9% of Oncologix Tech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares SurModics and Oncologix Tech’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SurModics $100.08 million 4.64 $7.59 million $0.72 47.49
Oncologix Tech N/A N/A N/A N/A N/A

SurModics has higher revenue and earnings than Oncologix Tech.


SurModics beats Oncologix Tech on 7 of the 9 factors compared between the two stocks.

About SurModics

Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment designs, develops, and manufactures interventional medical devices primarily for the peripheral vascular market; and offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. The Vitro Diagnostics segment provides stabilization products, substrates, antigens, and surface coatings to diagnostics customers; and manufactures or sells components for in vitro diagnostic immunoassay and molecular tests, as well as surface coatings to the diagnostic, biomedical research, and life science markets. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

About Oncologix Tech

Oncologix Tech, Inc., a diversified medical holding company, provides health care services in the United States. It offers personal home care services, including daily living assistance, companionship, and homemaker services, as well as Alzheimer's care, home care resource planning, and medical care coordination services. The company also manufactures, markets, and distributes medical technologies and products for skilled nursing facilities, acute and critical care facilities, assisted living facilities, hospitals and medical institutions, federal agencies, home medical care industry, respiratory and therapy- physical/occupational therapy centers. In addition, it distributes and sells home medical equipment for sleep and respiratory therapies; supplies and services durable medical equipment to treat obstructive Sleep Apnea; C-PAP and BiPAP oxygen equipment, a large selection of mask interfaces; and offers personalized treatment plans, as well as monitoring and support services. The company was formerly known as BestNet Communications Corp. and changed its name to Oncologix Tech, Inc. in January 2007. Oncologix Tech, Inc. was founded in 1995 and is based in Lafayette, Louisiana.

Receive News & Ratings for SurModics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics and related companies with MarketBeat.com's FREE daily email newsletter.